CA3050104A1 - Ppary agonist for the treatment of huntington's disease - Google Patents

Ppary agonist for the treatment of huntington's disease Download PDF

Info

Publication number
CA3050104A1
CA3050104A1 CA3050104A CA3050104A CA3050104A1 CA 3050104 A1 CA3050104 A1 CA 3050104A1 CA 3050104 A CA3050104 A CA 3050104A CA 3050104 A CA3050104 A CA 3050104A CA 3050104 A1 CA3050104 A1 CA 3050104A1
Authority
CA
Canada
Prior art keywords
subject
disease
huntington
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3050104A
Other languages
English (en)
French (fr)
Inventor
Barbara FINCK
Lawrence Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherus Oncology Inc
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of CA3050104A1 publication Critical patent/CA3050104A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3050104A 2017-01-18 2018-01-18 Ppary agonist for the treatment of huntington's disease Abandoned CA3050104A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447741P 2017-01-18 2017-01-18
US62/447,741 2017-01-18
PCT/US2018/014240 WO2018136635A1 (en) 2017-01-18 2018-01-18 Pparϒ agonist for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
CA3050104A1 true CA3050104A1 (en) 2018-07-26

Family

ID=62908392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3050104A Abandoned CA3050104A1 (en) 2017-01-18 2018-01-18 Ppary agonist for the treatment of huntington's disease

Country Status (13)

Country Link
US (1) US20190350918A1 (cg-RX-API-DMAC10.html)
EP (1) EP3570841A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020505448A (cg-RX-API-DMAC10.html)
KR (1) KR20190122664A (cg-RX-API-DMAC10.html)
CN (1) CN110461330A (cg-RX-API-DMAC10.html)
AU (1) AU2018210165A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019014529A2 (cg-RX-API-DMAC10.html)
CA (1) CA3050104A1 (cg-RX-API-DMAC10.html)
EA (1) EA201991716A1 (cg-RX-API-DMAC10.html)
IL (1) IL268008A (cg-RX-API-DMAC10.html)
MX (1) MX2019008535A (cg-RX-API-DMAC10.html)
SG (1) SG11201906644YA (cg-RX-API-DMAC10.html)
WO (1) WO2018136635A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895541B2 (en) * 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
MX2007004536A (es) * 2004-10-13 2007-07-17 Univ Connecticut Ligandos de lipido canabinergico.
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
WO2011002939A1 (en) * 2009-07-01 2011-01-06 Nutrition 21, Inc. Chromium complexes as enhancers of brain glucose transporters
BR112016014507A2 (pt) * 2013-12-20 2018-05-22 Teva Pharma uso de laquinimod para retardar progressão da doença de huntington

Also Published As

Publication number Publication date
MX2019008535A (es) 2019-12-02
EP3570841A4 (en) 2020-08-19
AU2018210165A1 (en) 2019-08-01
US20190350918A1 (en) 2019-11-21
EP3570841A1 (en) 2019-11-27
JP2020505448A (ja) 2020-02-20
WO2018136635A1 (en) 2018-07-26
CN110461330A (zh) 2019-11-15
KR20190122664A (ko) 2019-10-30
EA201991716A1 (ru) 2020-02-04
SG11201906644YA (en) 2019-08-27
IL268008A (en) 2019-09-26
BR112019014529A2 (pt) 2020-02-27

Similar Documents

Publication Publication Date Title
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
JP6957602B2 (ja) 神経変性疾患のための治療薬
NZ745778A (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
TW200936127A (en) Use of cannabinoids in combination with an anti-psychotic medicament
US20100063116A1 (en) Use of pramipexole or a salt thereof for the treatment of parkinson's disease
US10653652B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
HUE024558T2 (hu) Biotin alkalmazása szklerózis multiplex kezelésére
RU2763425C2 (ru) Терапевтические агенты для нейродегенеративных заболеваний
CN112566641A (zh) 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物
CN107660147A (zh) 用于治疗帕金森病和相关障碍的组合物
CN110996951A (zh) 治疗进行性核上性麻痹的PPARγ激动剂
Zafonte et al. Antispasticity medications: uses and limitations of enteral therapy
CN114728012A (zh) 用于治疗癫痫持续状态的加奈索酮
CN102143687A (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
JP2021519349A (ja) 幻覚とそれに関連する病態の治療のための方法および組成物
JPH07505646A (ja) 神経伝達速度の減損を伴う障害，特に糖尿病性ニューロパシーに対するアンギオテンシンｉｉアンタゴニスト
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
EP1938814A1 (en) Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
US20190350918A1 (en) PPARy AGONIST FOR TREATMENT OF HUNTINGTON'S DISEASE
JP2002541198A (ja) 失禁の治療法
Ciccone Geriatric pharmacology
JP2003535134A (ja) 痴呆治療剤
US20220401456A1 (en) Methods and compositions for treating seizure disorders in pediatric patients
US20200038420A1 (en) Aminosterol compositions and methods of using the same for treating depression
TW202539621A (zh) 用於治療巴金森氏症的治療劑

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240501